Vitalist US

Vitalis is a clinical-stage pharmaceutical company focused on developing innovative therapies for the treatment of moderate-to-severe pain and other chronic conditions. The company's lead program, VTS-72, is a novel small molecule designed to provide potent analgesia with a reduced risk of side effects compared to traditional opioids. Vitalis leverages its expertise in drug delivery and formulation to optimize the therapeutic profile of its candidates. The company aims to address significant unmet needs in the pain management market through its diverse pipeline of candidates. Vitalis is headquartered in the United States and continues to advance its clinical programs toward commercialization.